Bellevue Gold Limited (ASX:BGL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
With its stock down 30% over the past three months, it is easy to disregard Bellevue Gold (ASX:BGL). But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. In this article, we decided to focus on Bellevue Gold's ROE.
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
ROE can be calculated by using the formula:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for Bellevue Gold is:
12% = AU$85m ÷ AU$720m (Based on the trailing twelve months to December 2024).
The 'return' is the yearly profit. That means that for every A$1 worth of shareholders' equity, the company generated A$0.12 in profit.
View our latest analysis for Bellevue Gold
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
To begin with, Bellevue Gold seems to have a respectable ROE. Further, the company's ROE is similar to the industry average of 12%. This probably goes some way in explaining Bellevue Gold's significant 53% net income growth over the past five years amongst other factors. However, there could also be other drivers behind this growth. Such as - high earnings retention or an efficient management in place.
We then compared Bellevue Gold's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 20% in the same 5-year period.
Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. Is Bellevue Gold fairly valued compared to other companies? These 3 valuation measures might help you decide.
Given that Bellevue Gold doesn't pay any regular dividends to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.
In total, we are pretty happy with Bellevue Gold's performance. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. Unsurprisingly, this has led to an impressive earnings growth. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
2 hours ago
- Business Insider
UBS Sticks to Its Sell Rating for ASX (ASXFF)
UBS analyst Kieren Chidgey maintained a Sell rating on ASX (ASXFF – Research Report) today and set a price target of A$69.10. The company's shares closed last Tuesday at $45.35. Confident Investing Starts Here: Chidgey covers the Financial sector, focusing on stocks such as ASX , Insurance Australia Group Limited, and QBE Insurance Group Limited. According to TipRanks, Chidgey has an average return of -0.4% and a 52.38% success rate on recommended stocks. In addition to UBS, ASX also received a Sell from Morgan Stanley's Andrei Stadnik in a report issued yesterday. However, on the same day, Citi maintained a Hold rating on ASX (Other OTC: ASXFF).


Business Insider
3 hours ago
- Business Insider
ASX (ASXFF) Gets a Hold from Citi
Citi analyst Nigel Pittaway maintained a Hold rating on ASX (ASXFF – Research Report) today and set a price target of A$71.60. The company's shares closed last Tuesday at $45.35. Confident Investing Starts Here: According to TipRanks, Pittaway is a 4-star analyst with an average return of 3.6% and a 57.44% success rate. Pittaway covers the Financial sector, focusing on stocks such as Challenger , QBE Insurance Group Limited, and ASX . The word on The Street in general, suggests a Moderate Sell analyst consensus rating for ASX with a $42.99 average price target. The company has a one-year high of $50.05 and a one-year low of $36.25. Currently, ASX has an average volume of 641.
Yahoo
4 hours ago
- Yahoo
ASX Penny Stocks: EMVision Medical Devices Leads Our Trio Of Picks
As Australian shares are set to advance slightly, buoyed by positive U.S. inflation data and a stable commodities market, investors are keenly observing the opportunities within the local stock landscape. Despite its vintage feel, the term 'penny stocks' continues to hold relevance for those interested in smaller or newer companies that offer both affordability and growth potential. In this article, we explore three penny stocks that stand out for their financial strength and potential for long-term value creation. Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$1.735 A$81.85M ★★★★★★ GTN (ASX:GTN) A$0.605 A$115.47M ★★★★★★ IVE Group (ASX:IGL) A$2.76 A$425.54M ★★★★★☆ Southern Cross Electrical Engineering (ASX:SXE) A$1.67 A$441.56M ★★★★★★ Tasmea (ASX:TEA) A$3.10 A$730.43M ★★★★★☆ Regal Partners (ASX:RPL) A$2.22 A$746.28M ★★★★★★ Accent Group (ASX:AX1) A$1.805 A$1.09B ★★★★☆☆ Lindsay Australia (ASX:LAU) A$0.705 A$223.61M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.27 A$155.16M ★★★★★★ CTI Logistics (ASX:CLX) A$1.79 A$144.17M ★★★★☆☆ Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: EMVision Medical Devices Ltd focuses on the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, along with other medical imaging needs in Australia, with a market cap of A$156.92 million. Operations: The company generates revenue primarily from the research and development of medical device technology, amounting to A$8.06 million. Market Cap: A$156.92M EMVision Medical Devices Ltd, with a market cap of A$156.92 million, remains pre-revenue as it focuses on developing its neurodiagnostic technology. The company has more cash than debt and maintains a stable cash runway exceeding one year. Recent developments include the commencement of a pivotal trial for its emu™ Brain Scanner, aimed at stroke diagnosis and potentially supporting FDA clearance. This trial could pave the way for future product expansions in the medical imaging field. EMVision's board recently welcomed Carmel Monaghan as an Independent Non-Executive Director, bringing extensive healthcare experience to support strategic growth initiatives. Unlock comprehensive insights into our analysis of EMVision Medical Devices stock in this financial health report. Explore historical data to track EMVision Medical Devices' performance over time in our past results report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: LGI Limited focuses on carbon abatement and renewable energy solutions using biogas from landfill, with a market cap of A$267.31 million. Operations: The company generates revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Market Cap: A$267.31M LGI Limited, with a market cap of A$267.31 million, is generating revenue from Carbon Abatement (A$17.03 million), Renewable Energy (A$15.05 million), and Infrastructure Construction and Management (A$2.21 million). Despite the company's earnings contracting by 15.3% over the past year, its debt management remains strong with operating cash flow covering 34.4% of its debt and a reduced debt-to-equity ratio from 146.5% to 46.2% over five years. While LGI's net profit margin has decreased to 17.4%, it maintains stable weekly volatility at 4%. The board is experienced, though management tenure averages only 1.3 years. Click here to discover the nuances of LGI with our detailed analytical financial health report. Understand LGI's earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: NRW Holdings Limited, with a market cap of A$1.36 billion, offers diversified contract services to the resources and infrastructure sectors in Australia through its subsidiaries. Operations: NRW Holdings generates revenue from three main segments: Mining at A$1.56 billion, MET at A$853.22 million, and Civil at A$776.06 million. Market Cap: A$1.36B NRW Holdings, with a market cap of A$1.36 billion, demonstrates strong financial health through well-covered interest payments and operating cash flow that exceeds its debt by a large margin. The company's earnings have grown significantly by 29.9% over the past year, surpassing both its historical average and industry growth rates. Despite having low return on equity at 17.3%, NRW is trading below estimated fair value and has not diluted shareholders recently. Short-term assets exceed liabilities, indicating robust liquidity management, while recent executive changes bring seasoned leadership to the finance team with Peter Bryant as CFO starting in May 2025. Navigate through the intricacies of NRW Holdings with our comprehensive balance sheet health report here. Evaluate NRW Holdings' prospects by accessing our earnings growth report. Click this link to deep-dive into the 1,006 companies within our ASX Penny Stocks screener. Looking For Alternative Opportunities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:EMV ASX:LGI and ASX:NWH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio